Targeted News Service

CHMP recommends approval of Johnson & Johnson's TALVEY(r)V (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma
October 16, 2026

NEW BRUNSWICK, New Jersey, Oct. 16 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

CHMP recommends approval of Johnson & Johnson's TALVEY(r)V (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma

*

BEERSE, BELGIUM (16 October, 2026) - Johnson & Johnson, a worldwide leader in multiple myeloma, today announced that the Committee for Medicina . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form